News | September 09, 2013

TriGuard TAVI Embolic Protection Device Receives European Approval

September 9, 2013 — Keystone Heart, a company in the development of cerebral protection devices for interventional cardiology and cardiac surgery procedures, announced its TriGuard cerebral protection device has received CE mark, enabling the company to commercially market the TriGuard in Europe and other territories.

The TriGuard is the only device designed to cover all three aortic cerebral branches to minimize the risk of cerebral damage during transcatheter aortic valve replacement (TAVR) and other cardiovascular procedures. It is the only system designed for placement via one of two femoral artery access ports. The TriGuard accommodates most anatomical variations of the aortic arch and uses a nitinol frame and mesh.

The preservation of cerebral function throughout medical procedures is a key component to procedural success and patient care. Dr. Andreas Baumbach, consultant cardiologist at University Hospitals Bristol, United Kingdom, and honorary reader in cardiology at the University of Bristol, said "The device has the potential to become a routine preventive measure in TAVI and other cardiovascular procedures associated with embolic lesions. European approval of the TriGuard device is an important advancement in patient care."

New scientific data presented at EuroPCR demonstrated a significant reduction of new brain lesion volume during TAVR using TriGuard, compared with historical data on unprotected TAVR procedures. The clinical data shows that maximum total lesion volume was 95 percent smaller and average total lesion volume was 57 percent smaller when compared with historical references.

The medical community is witnessing heightened focus and scrutiny on cerebral injury concurrent with cardiovascular procedures, and research on possible preventative measures and devices to protect against brain injury has increased. Data from the PARTNER A study show nearly twice as many strokes in the TAVR group compared with the surgical aortic valve replacement group at 30 days, the majority of strokes being peri-procedural and within the first 2 days. In addition, newer "next-generation" TAVR devices have so far have apparently failed to reduce TAVR-related risk of stroke. These data affirm that protecting the brain is an important goal during TAVR.

The TriGuard device is not yet commercially available in the United States.

For more information: www.keystoneheart.com

Related Content

Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Sponsored Content | Videos | Heart Valve Technology| August 30, 2017
Azeem Latib, M.D., MBBCh, FCP, interventional cardiologist at Columbus Hospital in Milan, Italy, discusses the latest
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices| August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
CMS Awards New Technology Add-on Payment for Perceval Sutureless Aortic Heart Valve
News | Heart Valve Technology| August 22, 2017
August 22, 2017 — LivaNova PLC announced its Perceval ...
Overlay Init